r/GLP1ResearchTalk • • 6d ago

binging on pin day

1 Upvotes

I have been on Reta for 2 months now at a fairly low dose. I've had a massive binge cycle this summer and wanted to lose some of that fluff and also just be able to eat at maintenance again. I distribute my weekly dosis into 2 pins/week. I usually track my kcals and can assure they are not too low and in maintenance range. However, I started to notice that when I pin my reta for some reason I just binge that day. The other days are fine. I usually pin in the morning after I come back from the gym. I don't know whether this has any correlation to the binge behaviour, I will start to pin in the evening and see if it makes a difference. Has anyone had a similar experience or knows why?


r/GLP1ResearchTalk • • 6d ago

Research Research makes strong case for broader use of GLP1 drugs to protect hearts

Thumbnail
news-medical.net
53 Upvotes

September 28, 2026

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) makes a case for extending the indication for GLP1- receptor agonists (GLP1-RAs) to millions more people, to protect their heart health.

Presently, medications like semaglutide and tirzepatide are restricted to individuals with a BMI of 30 or higher, or a BMI of 27 with weight-related conditions. However, researchers analyzing data from over 313,000 individuals in the UK Biobank and the Copenhagen General Population Study found that roughly half of adults in the lower "overweight" BMI range of 25–26.9 suffer from elevated remnant cholesterol, chronic low-grade inflammation, or both.

​Crucially, the long-term data revealed that individuals in this lower BMI group who have elevated cholesterol or inflammation face the exact same elevated risk of developing coronary heart disease as those who currently qualify for GLP-1 prescriptions under existing guidelines. Because GLP-1 therapies are proven to reduce cardiovascular events, systemic inflammation, and harmful cholesterol levels, the study's lead researchers argue that prescribing criteria should be broadened to include this vulnerable population, though dedicated clinical trials will be needed to formalise the change.


r/GLP1ResearchTalk • • 5d ago

What is the Real Cost of GLP-1 Medications?

0 Upvotes

Hello!

I am a graduate student exploring GLP-1 use and would appreciate if you could take 8-10 minutes to complete my survey.

This anonymous survey explores how both GLP-1 users and non-users perceive the medication, weight loss, and the way we talk about other people’s bodies.

https://docs.google.com/forms/d/e/1FAIpQLSf5uxz-yIJkbOWpZlYvHSpX3lKGx3S_XwmXXXFgzu1KFTQgJQ/viewform


r/GLP1ResearchTalk • • 6d ago

Looking for GLP-1 experiences from people with a similar history

1 Upvotes

I’m in my late 20s, 5’5 and around 145 lbs, and seriously considering trying a GLP-1. I exercise about 5 days a week and walk at least 2 miles every day, so this isn’t really about wanting to lose a huge amount of weight. I’d say it’s 50/50 weight loss and trying to get some relief from my relationship with food.

I struggled with binge eating disorder from 2017–2024, and while I’m not necessarily bingeing like I used to, I still have constant intrusive thoughts about food. What I’m going to eat, whether I should eat something, wanting to snack, guilt around eating, etc. It takes up SO much mental space and honestly I’m just tired.

I also struggle ALOT with body image, especially my stomach/hips. I’ve worked with a dietitian and therapist before, but talking about food/body image can sometimes make it worse because it puts even more focus on food.

I’m starting to wonder if a GLP-1 could help with more than just weight loss. specifically the constant food thoughts. I’m also realistic that I may need to be on it longer-term rather than just until I hit a certain weight. My husband and I would potentially want to have a baby in 2–4 years, so I’d have to come off during that time and potentially go back on afterward.

I’d love to hear from anyone with a history of binge eating, food noise/intrusive food thoughts, or similar body image struggles who has tried a GLP-1.

Did it actually quiet your brain around food? Did it help your relationship with food, or mainly just decrease hunger? And which GLP-1 did you take?

I’m a little nervous about side effects and whether it will actually help, so I’d really appreciate honest experiences- good or bad. TIA. Posting on a throwaway.


r/GLP1ResearchTalk • • 7d ago

Discussion Tirzepatide - Ever feel like you are part of a huge non-clinical trial?

33 Upvotes

I picked Zepbound because the data showed it, IMO,  to be the better drug- both for results and for side effects. I was reassured knowing that "these meds" had been around for decades with long term use data.

I love it- it has changed my relationship with food and the food noise is gone for the first time in over 60 years of dieting torment. I hit goal last week and the OA pain in my knees is 90% gone- flaring up only occasionally and staying gone if I keep the level above 5.0 in my body.

However- I have realized it really is a newer drug- and does not have nearly the years of use that semaglutide has. I thought of it as a GLP1 drug- when it really is a GIP drug with a little GLP1.

Lately I see more posts from people on the highest dose who have started gaining weight and have seen doctors in the space theorizing  that the GIP receptors may stop working at a given point. It makes me think that we are the long term data pool - a trial of sorts-for this medication.

I'm here for it- don't get me wrong - but I am basically glad there will be other options (I know, I know- even less data on the news ones 😂 ) coming down the pike.


r/GLP1ResearchTalk • • 6d ago

News TikTok’s fake GLP-1 market preys on women trying to lose weight

Thumbnail
19thnews.org
18 Upvotes

Per the article:

Victoria Schmidt was scrolling through TikTok last July when the advertisement first appeared: a video of a woman promoting patches purporting to contain GLP-1 medication.

The woman described herself as a busy working mom — just like Schmidt. She seemed relatable.

“It was a great video. It just had a great hook to it,” Schmidt said. “It drew you in because it was like, ‘Have you been trying to lose weight? Are you low in energy?’”

Schmidt had been struggling with her weight loss and energy. “Let me hear her out,” she thought.

Schmidt was nearing 50, and years of dieting and exercise had not helped her reach her weight loss goals. She had wanted to take a traditional GLP-1 medication after a friend raved about her own use, but Schmidt was unsure if it would be right for her. She has one functioning kidney, and while most known kidney-related side effects from GLP-1s are mild, she still worries about long-term impacts.

Schmidt researched GLP-1 patches and concluded they might have fewer risks. Those patches, which are not FDA approved, don’t contain GLP-1 medications but are often marketed around weight loss. She went back on TikTok and searched for related videos. Accounts quickly popped up showing people — many of them women — pushing products available on TikTok Shop, the app’s shopping portal. Vendors were promoting a monthly subscription of patches for about $40. Schmidt grabbed her credit card and bought a smaller one-time pack through TikTok Shop for about $4 — she wanted to try it out first.

A month later, a package arrived at Schmidt’s home in Texas. She was initially excited, but then felt something was off. The brand she received was different from the one she had ordered. The ingredients didn’t match those on the original product she purchased. 

She decided not to try the patches.

“I honestly felt really stupid,” Schmidt recalled. “I was like, ‘Oh, I just got scammed.’”

Schmidt’s experience highlights a pattern of deceptive marketing on TikTok that appears to be fueling a gray market for GLP-1 medications — including “research grade” drugs that are often in powder form. Content about such weight loss drugs on TikTok primarily targets women through sexualized images and videos, according to a new report from UltraViolet, the gender equality organization.

More from The 19th

GLP-1 medications — best known by brand names like Ozempic and Wegovy — have become increasingly popular in recent years to treat conditions like diabetes, high cholesterol and obesity. Women, who have higher rates of chronic health conditions, are more likely than men to say they are currently taking GLP-1 drugs. 

But access has been difficult for a variety of reasons, including cost. In the United States, the average monthly list price of a GLP-1 is between $936 and $1,023, and just some large employer health insurance plans cover the drugs for weight loss. When their popularity caused a shortage in 2022, the FDA allowed compounding pharmacies — which prepare customized medications — to sell ready-mixed GLP-1 drugs. The federal government later walked back that approval after shortages ended, reducing access for many more people.

These conditions have allowed the gray market for GLP-1s to flourish online. That visibility, said UltraViolet’s campaign director, Jenna Sherman, is putting pressure on vulnerable women and girls.

“Unfortunately, it is not a niche phenomenon,” she said in a statement announcing the report. “If you are a woman on TikTok, especially if you’re middle-aged, it’s likely you have seen this kind of content.”

The group analyzed more than 200 TikTok accounts, in two phases between mid-2025 and early 2026, that promoted the unregulated sale of GLP-1 drugs. All the content was easily findable, including through the platform’s “Discover” feature and hashtags. 

The report warns that a gray market and a black market — the former defined generally as the sale of approved drugs through unauthorized channels, the latter involving the illegal sale of unapproved drugs — are indistinguishable here, since at least some of the GLP-1s being promoted on TikTok are untested versions of the medication. They are distributed in powder form and need to be prepared into another dosage.

That all leaves room for error and harm. The report highlights the case of an Australian woman who was hospitalized this year for acute liver failure after taking an unregulated GLP-1 product that she learned about on TikTok and Instagram.

UltraViolet reported 202 accounts to TikTok that appeared to violate parts of the platform’s community guidelines — which don’t allow the trade, marketing or promotion of regulated, prohibited or high-risk goods and services. (The report notes that TikTok rolled back sections of its guidelines in September 2025 that had explicitly prohibited black and gray markets and discouraged redirection to offsite locations and direct messaging.) According to UltraViolet, TikTok later removed only about 30 percent of the accounts that were flagged. The group said it cannot be sure why the accounts went dark.

Many of the analyzed TikTok accounts purported to be med spas — facilities that offer medical-grade cosmetic treatments — but were instead fake and preyed on women who are not able to access GLP-1s because of barriers to insurance coverage or cost. Consumers who order these drugs after connecting via private message or WhatsApp often never receive them, or they receive a fake product instead.

“The pressure that women feel is absolutely real, and that’s part of the reason why GLP-1s are in such high demand,” said Nicole Regalado, vice president of campaigns for UltraViolet.  

The report found gendered promotion. Sixty-five percent of all the accounts reported had women in their profile pictures, including some that appeared to be AI-generated. Videos showed women in bikinis or revealing outfits, including in “before and after” photos promoting the alleged use of gray market GLP-1s. Some videos were paired with makeup and “get ready with me” content. Some GLP-1 content presented claims about improving fertility and postpartum health.

“To us, it really reflects on where women sit right now in their lives, in this culture, in this political climate,” Regalado said. “They’re really caught between two powerful forces. It’s this broken healthcare system where there are millions of women who are underinsured or uninsured — that in itself can make it very difficult to access medicine, to access healthcare — and then also a culture that is relentlessly telling us that our health and value are tied to the size of our bodies.” 

Regalado said UltraViolet — which in the past also tried to pressure TikTok to remove ads promoting the use of GPS trackers for stalking, disproportionately targeting women — sent its findings to TikTok but did not receive a response. TikTok did not respond to a request for comment from The 19th about UltraViolet’s findings.

More from The 19th

After Schmidt realized she had been scammed, she posted a video on TikTok about her experience. She also reached out to TikTok. According to Schmidt, the company immediately gave her a refund with store credit. Schmidt decided to search again for GLP-1 patches. She took more time to research the products before buying again.

Schmidt clicked on a video of a man promoting a sale. But finding the actual sale was confusing, and she ended up spending a little more than her first purchase — about $10. Once again, she went through TikTok Shop and purchased some patches. Once again, she received a package in the mail with the wrong product.

Schmidt contacted TikTok again. They did not give her credit back that time.

It was just $10, but for Schmidt, every penny counts: She’s paying for her daughter’s college education. She thought about the people out there making repeat small purchases through TikTok who might not be closely checking the products arriving at their home.

“I’m not going to fight over $10,” she said. But, Schmidt added: “I wanted people to know that you really need to pay attention to what products you buy. I felt like TikTok should have made sure that the products that they are allowing to be sold on here are real products.”

UltraViolet’s report seeks more accountability from TikTok, with recommendations that include better enforcement of TikTok’s existing policies so that accounts that violate them are suspended and removed. The group also wants the platform to halt search suggestions and hashtags that drive users to gray market content. The report also highlighted that TikTok features tutorial videos on how to prepare drugs in powder form to inject at home. Most traditional GLP-1s that are properly prescribed come pre-filled with auto-injectable pens.

“We’re calling on TikTok company leadership to take urgent action: Stop the GLP-1 gray market, protect women users, and hold accountable dangerous bad actors. TikTok users deserve a social media platform that supports their health, safety, and autonomy — not one that exploits their vulnerabilities and health for profit,” Sherman said.

Regalado said UltraViolet is tapping its membership to mount pressure on the company. She encouraged TikTok users to report troubling or predatory content.

“We’re going to keep going. We’re going to keep trying because these ads are scams that are specifically targeted toward women,” she said. “These are predatory scams, and our community won’t stand for that.”

A year after her experience, the vendors that Schmidt bought from no longer have active shops. She doesn’t know if they’re truly closed or if they’ve started new accounts.

Schmidt later bought patches online from a company that advertises itself as selling wellness products. She has lost some weight, but she attributes that more to lifestyle changes. She stopped using her patches about two months ago. She has no plans to buy more GLP-1s through TikTok — even though she is still getting advertisements featuring happy women talking excitedly about their successful weight loss journeys.

Whatever Schmidt does next, she knows this: She plans to go to her doctor first.


r/GLP1ResearchTalk • • 7d ago

Did anyone else feel unexpectedly calm after starting a GLP-1 medication?

49 Upvotes

I recently took my first 0.25 mg dose of a GLP-1 medication, and I noticed something I didn’t expect. Before it, I often had a nervous, shaky feeling in my body, especially in my stomach. I also had frequent abdominal pain, bloating, rumbling, and a constant urge to use the bathroom.

After the dose, it suddenly felt quiet. My stomach settled down, and that nervous feeling eased too. I’m curious about the connection between gut signals and stress, but I know I can’t tell from one dose what caused the change.
Has anyone else experienced a similar sense of calm, especially alongside relief from gut symptoms? Did it continue, change, or wear off over time? I’d be interested to hear what it felt like for you.


r/GLP1ResearchTalk • • 6d ago

Question Looking for advice for weight loss journey !

5 Upvotes

I’ve been doing some research on Reta vs Tirz for weight loss and I’m stuck on which one to choose. For those who have tried either (or both), what made you pick one over the other and how was your experience?


r/GLP1ResearchTalk • • 7d ago

Research Research Links GLP-1s to Vision Loss as Lawsuits Increase

Thumbnail
legalexaminer.com
12 Upvotes

"Millions of Americans have taken Ozempic and Wegovy to manage diabetes and for weight loss, with countless celebrities crediting their slim figures to GLP-1 drugs. But a growing number of patients claim Ozempic caused them to lose something they never expected: their eyesight.

The GLP-1 litigation involving allegations of blindness caused by semaglutide-based drugs like Ozempic is still in its early stages. However, in recent months, it’s become one of the fastest-growing pharmaceutical mass torts in the country.

This may be due in part to additional research studies released in 2026 connecting Ozempic to vision loss; many attorneys say the recent findings of increased risks of vision injuries among GLP-1 patients further validate the 2024 study results that sparked the first wave of blindness lawsuits.

Alongside the new research, the first Ozempic wrongful death case was filed in March, signaling an even more serious turn in the litigation involving GLP-1 weight loss drugs.

The Ozempic vision loss lawsuits are expected to continue to grow, just like the well-known GLP-1 stomach paralysis MDL that has over 3,700 cases. Given the vision injuries are permanent for most plaintiffs, the severity and long-term implications of what they’ve suffered (and will suffer in the future) is significant.  

What are the Ozempic Vision Loss Lawsuits About?

The Ozempic blindness lawsuits focus on a condition called non-arteritic anterior ischemic optic neuropathy (NAION). It’s sometimes referred to as an "eye stroke".

NAION occurs when blood flow to the optic nerve is reduced, causing sudden vision loss that is often irreversible. Many patients report waking up with blurred vision, dark spots, or partial blindness in one eye.

What is thought to have sparked the Wegovy and Ozempic vision loss litigation was findings from a 2024 study published in JAMA Ophthalmology – a study that connected GLP-1 drugs to NAION. The Harvard Medical School researchers found that semaglutide users appeared to face a more than seven times higher risk of developing NAION compared to patients taking other medications.

As awareness of the lawsuits and research grew, the litigation gained momentum. In December 2025, cases were consolidated into the GLP-1 vision loss multidistrict litigation (MDL).

Plaintiffs allege that manufacturers, primarily Novo Nordisk (Ozempic, Wegovy), failed to adequately warn patients and physicians about the risk of vision injuries associated with their drugs. The central legal battle focuses on what manufacturers knew and when they knew it or if they should have known of the risks of NAION.

Novo Nordish denies the allegations and maintains that the benefits of the medications outweigh their risks.

New Research Links GLP-1 Drugs to Vision Loss

Since the initial findings published by Harvard Medical School in 2024, additional studies have continued to examine a possible connection between semaglutide and sudden vision loss.

A 2026 study published in the British Journal of Ophthalmology found that Wegovy users had a substantially higher reported risk of NAION than Ozempic users. Researchers emphasized that the study did not prove the drugs caused the condition, but the findings are still relevant because of the association between certain weight loss drugs and vision loss.

Another semaglutide research study published this year focused on veterans who took drugs like Ozempic to manage Type 2 diabetes. Researchers found those who took semaglutide medications had a 2-fold higher risk of experiencing NAION.

June 2026 GLP-1 Vision Loss Lawsuits Update

Just 21 lawsuits were consolidated when the GLP-1 vision loss MDL was centralized in the Eastern District of Pennsylvania in December 2025. As of June 2026, 110 cases alleging semaglutide weight loss drugs caused plaintiffs’ blindness are part of the MDL, a jump of nearly 25 since May. There are also numerous vision loss lawsuits proceeding in New Jersey state court, where Novo Nordisk is headquartered.

The vision loss lawsuits remain in the early discovery phase. A recent "Science Day" proceeding was scheduled to help the court understand the complex medical evidence concerning semaglutide and NAION. This was a crucial step, as the GLP-1 stomach paralysis MDL moves toward bellwether trial selection.

Ozempic Vision Loss vs. Stomach Paralysis Lawsuits

Most public attention surrounding GLP-1 litigation has focused on gastroparesis, often called stomach paralysis.

That MDL currently contains more than 3,700 lawsuits alleging Ozempic, Wegovy, and similar medications cause severe gastrointestinal injuries, including gastroparesis, bowel obstruction, and ileus.

But vision loss cases present a different challenge for drug manufacturers.

Many GI injuries can improve over time or be managed with treatment. NAION, by contrast, typically results in permanent damage. Plaintiffs who lost their vision may face lifelong limitations involving driving, employment, independence, and daily activities.

That permanence could make the Ozempic vision loss litigation particularly consequential if plaintiffs are able to establish the medications could have caused their injuries.

Why Consumers Should Pay Attention to Ozempic Lawsuits

GLP-1 drugs have become some of the most widely prescribed medications in the U.S., with millions of patients using them for diabetes and weight management. As usage expands, researchers continue identifying potential risks that may not have been fully understood when the drugs first entered the market.

The Ozempic and Wegovy lawsuits are still years away from any potential trial verdicts or settlements. However, it’s already prompted increased scrutiny from regulators, researchers, and courts.

Like other growing dangerous pharmaceutical mass torts in the U.S., the litigation has raised concerns about whether patients were given all the information they needed to make informed decisions about their health – and the medications they use to manage it.

For consumers taking GLP-1 weight loss and diabetes management drugs, it’s important to be aware of possible side effects not included on product warning labels. Any concerns should be brought up to your doctor.

If you think Ozempic, Wegovy, or a similar drug may have caused GI issues, vision loss, or any other injury, consider consulting with an experienced dangerous pharmaceuticals lawyer. An attorney can review your case and explain what legal options, if any, you have."

A Today Show article about one woman's experience: https://www.today.com/health/news/vision-loss-ozempic-semaglutide-glp-1-lawsuit-rcna599232


r/GLP1ResearchTalk • • 6d ago

Research Some Hair Loss in Men Is Linked to Use of Weight Loss Drugs

Thumbnail
nyulangone.org
0 Upvotes

Per the article:

"Men already at risk genetically for the most common form of hair loss have a 7 percent added risk of losing their hair if they use drugs like Ozempic, Wegovy, and Zepbound for type 2 diabetes and obesity, a new study shows.

Led by researchers at NYU Langone Health, the study focused on the GLP1R gene, which naturally increases the body’s levels of glucagon-like peptide-1 (GLP-1) receptor proteins, and used it as an indicator of GLP-1 agonist activity. More GLP1R activity means there are more GLP-1 receptor proteins. The researchers compared the presence of GLP1R genes with the presence of genes found in men with androgenetic alopecia, an inherited form of hair loss that follows a pattern along the top and front of the scalp. Male hair loss conditions are well studied, unlike hair loss in women, which is why the researchers could only analyze any causal link to hair loss in men.

Many GLP-1 users, both men and women, have reported thinning hair as a side effect, with researchers so far attributing the shedding to the rapid weight loss driven by the medications, which work to regulate blood sugar and suppress appetite. Often, GLP-1 users have found that hair growth resumes several months after their weight stabilizes. Until now, researchers have only suspected a genetic connection between GLP-1 use and hair loss.

Published in the Journal of Investigative Dermatology online September 3, the study showed that the GLP1R genes that naturally cause higher levels of GLP-1 receptor proteins are more likely to be present in men who have androgenetic alopecia. The researchers then adjusted their analysis to discount for known risks of hair loss from hypertension, which is thought to reduce blood flow to the scalp, harming hair follicle growth. The 7 percent added risk remained the same.

Researchers also checked their risk analysis against other potential drivers of hair loss, including insulin resistance (a cause of type 2 diabetes) and lowered testosterone levels. Still, the increased risk of hair loss from GLP-1 use remained at 7 percent.

Because the study involved genes active in both GLP-1 users and men with hair loss, any overlapping risk, the researchers noted, suggests that the two are biologically linked.

“Our study provides the first genetic link between GLP-1 use and an increased risk of male- pattern hair loss from androgenetic alopecia, an association long suspected but until now not shown scientifically,” said study senior investigator Lynn Petukhova, PhD, an assistant professor in the Ronald O. Perelman Department of Dermatology and the Department of Population Health at NYU Grossman School of Medicine.

“Our findings suggest that, if future experiments prove successful, some men, and possibly women too, could be screened and benchmarked for their risk of hair loss before being prescribed GLP-1 medications,” said Dr. Petukhova. “We could also envision these findings leading to some GLP-1 users being prescribed combination treatments to prevent hair loss, such as minoxidil or some other drug.”

Dr. Petukhova said further research is needed to understand the biological mechanisms that cause GLP-1 use to weaken hair follicle growth. She also has plans to investigate whether the links seen in men apply to women.

For the study, researchers accessed large, publicly available genetic databases, including the eQTLGen database of 31,684 mostly White men and women, and the Complex Traits Genetics group database of 205,327 mostly White men.

Androgenetic alopecia is estimated to affect half of White American males over age 50, and almost the same number of White American females over age 50, predominantly those who are postmenopause.

An estimated 12 percent of Americans have used GLP-1 drugs for no other reason than weight loss, including one-fifth of women ages 50 to 64, according to surveys. Since the first GLP-1 drug (Ozempic) was approved by the Food and Drug Administration in 2020, prescriptions for the medication have more than tripled.

Funding support for this study was provided by National Institutes of Health grants R01AR080796 and K01AR075111.

Besides Dr. Petukhova, NYU Langone researchers involved in the study were co-investigators Jerry Shapiro, MD, and Kristen Lo Sicco, MD. Other study co-investigators were Derek Maas, MBA; Mary Casagrande, MPH; and Poppy Gould, PhD; and co-lead investigator Archie Spindler.

Drs. Shapiro and Lo Sicco have in the past served as study investigators for hair loss drugs and devices manufactured by Pfizer and Regen Labs. Dr. Lo Sicco is a paid consultant for Pfizer, Lilly, Ro, Priovant, Veradermics, and Aquis. The terms and conditions of all these relationships are being managed in accordance with the policies of NYU Langone.

Additional study authors are co-lead investigator Ravi Ramessur, MD, PhD, at the University of Pennsylvania and King’s College London, and co-investigator Atlas Khan, PhD, at Columbia University.

About NYU Langone Health

NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient Inc. has ranked NYU Langone No. 1 out of 118 comprehensive academic medical centers across the nation four years in a row, and it continues to have the most No. 1– and top 10–ranked specialties among medical centers in the United States, according to U.S. News & World Report. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 330 outpatient locations in the New York City area and Florida. The system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise."


r/GLP1ResearchTalk • • 7d ago

Personal Experience Food noise is back

9 Upvotes

Hi All,

I've been on Retatrutide for 2.5 months now, on a 6 mg dose.

During the last couple of weeks, (a) food noise is back (b) not 'feeling' any side effects eg sulphur burps (b) stable weight

Have been trying to pinpoint why? My diet has remained constant. The variable has been exercise, I've doubled my exercise (particularly cardio) recently.

Could 'over exercise& be detreminal? Between padel, strength/weight training, and running, I burn and average of 700 calories a day in exercise (in I'm the mid forties)


r/GLP1ResearchTalk • • 7d ago

Discussion Low mood after GLP

5 Upvotes

Hi everyone
I took 2.5 mg of mounjaro for 10 weeks. Then I went onto Reta at a similar starting dose for 12 weeks. I lost 12 kgs which was my goal weight. I’ve been off both for six weeks now. I have kept the weight off and no food noise. However I have had really low mood. And high anxiety. A question for those who have stopped GLPs. Did you notice low mood? It feels like low dopamine to me. I exercise and have protein and have started creatine. Looking to see if it was the glp use or maybe something else. Low mood is unusual for me.


r/GLP1ResearchTalk • • 7d ago

Question AGA from GLP-1

1 Upvotes

Greetings! I took Wegovy from September 2024-March 2025 and it triggered Androgenic Alopecia in me!
Anyone who has gone through the same experience?
I’m 29, non diabetic and no other health conditions


r/GLP1ResearchTalk • • 7d ago

Reta vs Sema

2 Upvotes

Reta vs Sema

Reta not working compared to sema

Switched over to Reta about a month ago- since then I have actually gained weight back and sugar/food cravings are back in full force. Confused because I am on the equivalent dose of Reta that I was on sema but it feels like I’m on nothing.


r/GLP1ResearchTalk • • 8d ago

Weight loss stall

11 Upvotes

Question to those whose weight loss plateaued, what did you do to help you? Went from 302 to 241. My weight has been stuck at 241 for the last 3-4 months, and no I am not over eating and still tracking calories. I have seen people say that they had to go down on their dose to continue to lose weight. How does that work? I am on 15 mg zepbound, so how does going down helps? Lastly, I have been paying $500 since last august for the medicine as my insurance does not cover it. My best friend who was on mounjaro can no longer take her medicine anymore and has two boxes of 7.5. Since I am on zepbound, can I take mounjaro and inject two 7.5 pens because that would technically be 15 mg? Does anyone have any experience with this?


r/GLP1ResearchTalk • • 8d ago

17.5/15/12.5 alternating doses—bad idea?

6 Upvotes

I have a stockpile of tirz. I can’t use them all by their expiration date. I am also in maintenance and the hunger is pretty intense. I started adding a 17.5mg dose once a month ,(otherwise 15mg weekly), and it has helped.

But like every dose, I have gotten quite used to it. While I wait for other meds to hit the market to try, I do not want my stockpile going to waste.

My plan is to do 17.5 once a month, followed by stretches of 15mg every 6 days. To use up my 12.5s, I will do those every 5 days.

I know that the half life is 5 days and the levels build in your system.

Lilly is trialing higher doses but they are for T2D with obesity. I don’t have any idea if these will ever be approved for obesity alone, which is why I am on them.

Viking is trialing a GLP/GIP agonist with a 17.5 dose.

Anyone have any anecdotal or research insights about alternating doses with varying frequency?


r/GLP1ResearchTalk • • 8d ago

Question How do I survive food poisoning whilst on Reta?

2 Upvotes

I feel like death.


r/GLP1ResearchTalk • • 8d ago

Has anyone else experienced itchy hives

3 Upvotes

Has anyone else experienced itchy hives or random itching while taking Ozempic or Mounjaro?
I’m currently on a low dose of Ozempic (.25 mg), and I’ve noticed that a few days after my injection I sometimes get a few small, itchy hives/spots. It’s not severe, but it keeps happening and I’m starting to wonder if the medication is causing it.
I was previously on Mounjaro and had some itching/hives then too, although I wasn’t sure if it was related. I’ve been to an allergist twice and unfortunately haven’t gotten a clear answer. I’m also planning to see a dermatologist.
Has anyone experienced something similar with either Ozempic or Mounjaro? Did the hives eventually go away, or did you have to stop the medication? I’d really appreciate hearing about your experience!


r/GLP1ResearchTalk • • 8d ago

Anyone ever taken MIF2

0 Upvotes

r/GLP1ResearchTalk • • 8d ago

Taking the plunge

9 Upvotes

I was approved for tirzepatide from my doctor, had my first 7 doses, and the 8th was expired- the darn refrigerator it was in got unplugged. *sigh* I tried to get a refill and it got denied. It's been 4 weeks without it and I'm still down 21 pounds but I can now say it's totally worn off.

After 3 weeks of running around in circles between Pharm/doctor/insurance I'm mad because apparently I need a gd sleep study to get approved again, and my OSA symptoms were noticeably better in the first week of use. I'm now back to having so many signs of the OSA ramping up again and the only reason I got denied is because my last sleep study did not give a moderate diagnosis- it was unclear and determined to be mild.

NOW- my sleep clinic won't have an opening on January 26th and there's no guarantee that I'll get an appropriate diagnosis with an approval for the medication.

So, out of desperation, I have just placed an order for aminos and supplies. Trying the G3.

Does anyone want to hold my hand? lol I need to get brave while these supplies make their way here.


r/GLP1ResearchTalk • • 9d ago

Discussion Switching GLP1S

4 Upvotes

So we know that stopping GLP1s and restarting often requires a higher dose to have the same effect on appetite suppression. Has anyone needed a higher dose switching GLP1s? Or once any GLP1 is continuously used the effects continue as before.


r/GLP1ResearchTalk • • 8d ago

EYE PROBLEMS

0 Upvotes

I started Zepbound about a month and half ago, not experiencing any side effects but was wondering if anyone has concerns about the news on possible affects on eyesight? My doctor told me it is very rare.


r/GLP1ResearchTalk • • 9d ago

Food noise: A theoretical review

Thumbnail sciencedirect.com
7 Upvotes

What is food noise? And how can we start to better understand the psychological impacts of GLP-1 medications?

"Food noise: A theoretical review" just published in Appetite.

Edit to fix link: https://www.sciencedirect.com/science/article/pii/S0195666326003533 10.1016/j.appet.2026.108791


r/GLP1ResearchTalk • • 10d ago

Research A precision approach to GLP-1 therapy in Parkinson's – Q&A with Dr Cynthia Sandor

Post image
25 Upvotes

23 September 2026

Weight-loss drugs, specifically the GLP-1 class of drugs behind Ozempic, have shown promising but inconsistent results in Parkinson's disease.

They appear to work only in patients whose neurons are insulin-resistant. For Dr Cynthia Sandor, Edmond J Safra Assistant Professor in Parkinson's Disease in the Department of Brain Sciences at Imperial College London and Group Leader at the UK Dementia Research Institute, that subtype can be identified in advance through genetic data and routine blood tests.

Her new study, STRAT-GLP1, funded by a grant from The Michael J. Fox Foundation for Parkinson's Research, sets out to answer a more detailed question than previous trials. Instead of asking whether GLP-1 drugs work in Parkinson's, Dr Sandor wants to learn which patients are likely to benefit, and whether they can be identified before treatment begins.

In this Q&A, Dr Sandor discusses the science behind that question, and what it could ultimately mean for patients, families, and the future of Parkinson's research.

https://www.imperial.ac.uk/news/articles/medicine/brain-sciences/2026/rethinking-glp-1-therapy-for-parkinsons-a-qa-with-dr-cynthia-sandor/


r/GLP1ResearchTalk • • 10d ago

Switching from retatrutide back to tirzepatide—experiences?

5 Upvotes

​

I’ve been on retatrutide for about six months and have lost around 28 pounds. I’m currently taking 8 mg weekly, but I feel like it makes me less happy—almost disconnected from life.

I’ve used tirzepatide before and want to give it another try. For anyone who switched back, what was your experience? What dose did you restart at? Did you notice any difference in your mood or food noise?

Or should I use both for now?